RT Journal Article
SR Electronic
T1 Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia
JF Science Advances
JO Sci Adv
FD American Association for the Advancement of Science
SP eabc1564
DO 10.1126/sciadv.abc1564
VO 6
IS 31
A1 Park, Hee Ho
A1 Kim, Hong Nam
A1 Kim, Hyelim
A1 Yoo, Youngbum
A1 Shin, Hyosoo
A1 Choi, Eun Young
A1 Bae, Jong-Sup
A1 Lee, Wonhwa
YR 2020
UL http://advances.sciencemag.org/content/6/31/eabc1564.abstract
AB The outbreak of the highly contagious and deadly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19), has posed a serious threat to public health across the globe, calling for the development of effective diagnostic markers and therapeutics. Here, we report a highly reliable severity diagnostic biomarker, acetylated 676th lysine transforming growth factor–beta–induced protein (TGFBIp K676Ac). TGFBIp K676Ac was consistently elevated in the blood of patients with SARS-CoV-2 pneumonia (n = 113), especially in patients in the intensive care unit (ICU) compared to non-ICU patients. Patients’ blood samples showed increased cytokines and lymphopenia, which are exemplary indicators of SARS-CoV-2 pneumonia. Treatment with TGFBIp neutralizing antibodies suppressed the cytokine storm. The increased level of TGFBIp K676Ac in ICU patients suggests the promise of this protein as a reliable severity diagnostic biomarker for severe SARS-CoV-2 disease.